Innovaccer
Healthcare data and agentic AI platform, described by the company as an agentic cloud for healthcare, built in three stages: data connectivity integrating Epic, Cerner, MEDITECH, and Allscripts with payer claims, pharmacy, lab, remote monitoring, and social determinants sources across a reported 80 million plus patient records; applications on top of that data; and now autonomous agents. Gravity is the underlying data platform, continuously trained on real world healthcare data including claims denials and edge cases, which the company argues gives each new agent institutional context at launch. Sara is the AI assistant line spanning insights, care management, and clinical documentation via Sara Scribe. A suite of pretrained voice enabled agents covers appointment scheduling, protocol intake, referral management, routine patient inquiries, prior authorization, care gap closure, hierarchical condition category coding, and transitional care management, supporting clinicians, care managers, risk coders, patient navigators, and contact center staff. The stated architectural claim is end to end workflow connection: a prior authorization agent can hand off to coding and denial management agents rather than each operating in isolation. Reports serving six of the top 10 US health systems and more than 130 healthcare organizations, with named customers including Kaiser Permanente, Ascension, and Trinity Health. Best in KLAS recognition across data and analytics, population health management, and CRM categories. Founded 2014; $675 million raised in total including a $275 million Series F, with investors including Kaiser Permanente and Banner Health.
Capability Axes
The agent suite is genuinely model driven and the company has committed substantial capital to it. Held back from A because the durable asset underneath is the data platform: a decade of EHR, claims, pharmacy, lab, and social determinants integration across a reported 80 million patient records. The company's own argument is that agents work because the data layer gives them context, which correctly identifies the data as the foundation and the agents as what sits on top.
The distinguishing architectural claim is that agents hand off to one another end to end, with prior authorization passing work to coding and denial management rather than operating in isolation. That chaining is the value proposition and also the risk: an error introduced early propagates downstream without a documented checkpoint between stages. No escalation criteria, confidence thresholds, or human review gates were retrieved for any agent in the suite. Chained autonomous agents acting on coverage and coding decisions warrant published guardrails.
Adoption evidence is among the strongest in this index: six of the top 10 US health systems, more than 130 healthcare organizations, and named customers including Kaiser Permanente, Ascension, and Trinity Health. Kaiser Permanente and Banner Health both invested in the Series F while being customers, which is a materially stronger signal than a logo. Best in KLAS recognition spans three separate categories. Held back from nothing on adoption; note that outcome evidence for the newer agent suite specifically is thinner than the platform track record it inherits.
Data integration is the original business and remains the strongest axis. Connectivity spans Epic, Cerner, MEDITECH, and Allscripts plus payer claims feeds, pharmacy networks, lab systems, remote monitoring devices, and social determinants sources, assembled into unified records at a reported 80 million patient scale. Best in KLAS recognition in the data and analytics category is buyer survey based rather than vendor asserted.
No public pricing. Contact the vendor. Third party comparison notes custom enterprise pricing based on deployment size, users, and module scope. Buyers should establish whether agents are priced individually or as a platform bundle, since the end to end chaining argument only pays off if several are deployed.
Breadth is real and enumerated across population health, revenue cycle, payer risk and quality, utilization management, patient engagement, and public sector programs, serving providers, payers, government agencies, and life sciences. Held back from A because that range is very wide, and a buyer should establish which agents are production proven in their specific setting rather than assuming uniform maturity across a suite that expanded quickly.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Custom enterprise pricing by deployment size, users, and module scope | — | — | Third Party Estimated |
No rate card published. Third party comparison describes custom enterprise pricing scaled by deployment size, user count, and module scope. The structural question is whether agents are priced individually or bundled: the company's central architectural argument is that agents chain end to end across prior authorization, coding, and denial management, and that value only materializes if several are deployed, so per agent pricing would undercut the thesis.